Trial Profile
A Single arm, open, prospective study of Mesylate apatinib in the treatment of advanced bone and soft tissue sarcoma
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 11 Dec 2017
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Bone cancer; Soft tissue sarcoma
- Focus Therapeutic Use
- 11 Dec 2017 New trial record